October 27, 2021
Safety, PK and PD from Single Ascending Does Portion of KT-474 Phase 1 Trial in Healthy Volunteers
4th Annual TPD Summit
Atopic Dermatitis (AD)
Hidradenitis Suppurativa (HS)
Read More
October 26, 2021
TPD Workshop: De-risking Clinical Development of a Novel Protein Degrader
4th Annual TPD Summit
Atopic Dermatitis (AD)
Hidradenitis Suppurativa (HS)
Read More
September 21, 2021
Identification of Highly Potent and Selective Interleukin-1 Receptor Associates Kinase 4 (IRAK4) Degrader for the Treatment of Autoimmune Disease
European Protein Degradation Congress
Atopic Dermatitis (AD)
Hidradenitis Suppurativa (HS)
Read More
May 10, 2021
IRAK4 Degradation Abrogates Cytokine Release and Improves Disease Endpoints in Murine Models of IL-33/36- as well as Th17-driven Inflammation
American Association of Immunologists’ Virtual IMMUNOLOGY2021™ Annual Meeting
Atopic Dermatitis (AD)
Hidradenitis Suppurativa (HS)
Read More
May 3, 2021
Multiple Mediators of Inflammation Correlate with IRAK4 Expression in the Skin of Hidradenitis Suppurativa Patients and are Blocked by the IRAK4 Degrader KT-474 in TLR-activated Monocytes
Society for Investigative Dermatology (SID) 2021 Annual Meeting
Atopic Dermatitis (AD)
Hidradenitis Suppurativa (HS)
Read More
November 3, 2020
IRAK4 Degrader to Take on Innate Immunity
Mullard, A. IRAK4 degrader to take on innate immunity. Nat Biotechnol 38, 1221–1223 (2020)
Atopic Dermatitis (AD)
Hidradenitis Suppurativa (HS)
Read More
October 9, 2020
Interim results from non-interventional study to evaluate cutaneous and circulating biomarkers for a novel IRAK4-targeted therapeutic in patients with hidradenitis suppurativa
5th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA)
Hidradenitis Suppurativa (HS)
Read More
February 5, 2020
Identification of highly potent and selective Interleukin-1 receptor associated kinase 4 (IRAK4) degraders for the treatment of hidradenitis suppurativa
European Hidradenitis Suppurativa Foundation Scientific Conference
Hidradenitis Suppurativa (HS)
Read More
November 8, 2019
A first-in-class selective and potent IRAK4 degrader demonstrates robust in vitro and in vivo inhibition of TLR/IL-1R activation and inflammation
American College of Rheumatology Annual Meeting
Read More